drugset
drugset / Trial / NCT07044232

NICardipine for Fast Achievement of Systolic BP Targets in ICH

NCT07044232 ↗

Phase 4 Recruiting 88 enrolled Aarhus University Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

Quality improvement study with a quasi-randomized design. The study monitors the effect of a gradually implemented treatment algorithm prioritizing intravenous antihypertensives (e.g., nicardipine) over long-acting nitrate patches. It aims to increase the proportion of patients reaching target systolic BP \<140 mmHg within 1 hour of hospital admission while monitoring safety, clinical outcomes, and healthcare resource utilization.

Timeline

Start
2025-10-01
Primary completion
2026-09-30
Completion
2027-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Nicardipine Small molecule 2.5 mg Intravenous
Subject Nicardipine Small molecule 5 mg Intravenous
Subject Nitroglycerin Unknown 5 mg Other
Subject Nitroglycerin Unknown 10 mg Other
Background Labetalol Small molecule 10 mg Intravenous
Background Labetalol Small molecule 20 mg Intravenous
Background Methyldopa Unknown 250 mg Oral
Background Nimodipine Small molecule 30 mg Oral
Background Nimodipine Small molecule 60 mg Oral

Indications

intracerebral hemorrhage